![]() |
|
|

*
Center for Nutritional Sciences, Food Science and Human Nutrition Department, Institute of Food and Agricultural Sciences and
Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, FL 32611
2To whom correspondence should be addressed. E-mail: mcmahon{at}ufl.edu.
The effect of dietary antiepileptic drug administration on the metabolism and function of the water-soluble vitamin biotin was analyzed in a physiologically relevant rat model of biotin nutriture. Administration of carbamazepine (CBZ) in semipurified rat diet at 1.5 and 2.9 g/kg for 19 d did not reduce growth rate or food intake. After this dietary treatment, brain lactic acid and ammonia concentrations were significantly elevated, but no changes in these metabolites occurred in the liver. Urinary biotin excretion was altered and the concentrations of biotin sulfoxides and biocytin in the serum were elevated. Brain biotin was unaffected, but concentrations of bisnorbiotin and biocytin were significantly reduced by dietary administration of CBZ. The relative abundance of hepatic acetyl CoA carboxylase 1 and 2, pyruvate carboxylase (PC), methylcrotonyl CoA carboxylase and propionyl CoA carboxylase was significantly reduced by CBZ, whereas the relative abundance of biotinylated PC was significantly reduced in the brain. In agreement with the carboxylase abundance data, the activity of hepatic PC was significantly reduced in rats consuming CBZ-containing diets. These data demonstrate that administration of the antiepileptic medication CBZ, even with food, reduces the abundance and function of biotin-dependent enzymes in the liver and brain, partially accounting for the metabolic alterations, including organic acidemia, that are observed clinically.
KEY WORDS: biotin antiepileptic drug carbamazepine carboxylase rats
This article has been cited by other articles:
![]() |
S. C. Rathman, J. F. Gregory III, and R. J. McMahon Pharmacological Biotin Supplementation Maintains Biotin Status and Function in Rats Administered Dietary Carbamazepine J. Nutr., September 1, 2003; 133(9): 2857 - 2862. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Rathman, R. K. Blanchard, L. Badinga, J. F. Gregory III, S. Eisenschenk, and R. J. McMahon Dietary Carbamazepine Administration Decreases Liver Pyruvate Carboxylase Activity and Biotinylation by Decreasing Protein and mRNA Expression in Rats J. Nutr., July 1, 2003; 133(7): 2119 - 2124. [Abstract] [Full Text] [PDF] |
||||